Additional $85m funding injection for Ajax Health

Ajax Health has secured a further investment of over $85m from HealthQuest Capital, Aisling Capital and Polaris Partners, which will be used to operate and expand new medical device companies.
Duke Rohlen, Ajax Health chairman and CEO, held top executive roles at companies such as EPIX Therapeutics, Ajax Vascular, Spirox, CV Ingenuity and FoxHollow Technologies. He said: “I am extremely grateful to our partners HealthQuest, Aisling and Polaris for backing Ajax II. These firms have been exceptional partners for a long time and I look forward to working with them again.”
Garheng Kong, HealthQuest founder and managing partner, said: “Ajax Health approaches medical device innovation in a novel way, applying best-in-class strategies to pinpoint technologies with the greatest opportunity to take off, then rapidly developing them into a fully integrated business. Ajax Health’s proven executive team, led by Duke Rohlen, Doug Koo and Aftab Kherani, has shown an exceptional ability to develop medical technologies successfully and cost efficiently.”